Patents Assigned to GenVec, Inc.
  • Patent number: 11359214
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: June 14, 2022
    Assignee: GenVec, Inc.
    Inventors: Douglas E. Brough, Jason G. D. Gall, Duncan McVey
  • Patent number: 11279951
    Abstract: The invention is directed to a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding a human atonal homolog-1 (Hath1) protein operably linked to a human glial fibrillary acidic protein (GFAP) promoter. The invention also is directed to a composition and method utilizing the adenoviral vector to generate sensory cells in the inner ear of a human.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 22, 2022
    Assignee: GenVec, Inc.
    Inventors: Douglas E. Brough, Damodar R. Ettyreddy
  • Patent number: 11155832
    Abstract: The invention provides adenoviral vectors and compositions for the highly efficient transduction of T cells.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 26, 2021
    Assignee: GenVec, Inc.
    Inventors: Sebastien M. Maloveste, Damodar Ettyreddy, Douglas E. Brough
  • Publication number: 20210301303
    Abstract: The invention provides adenoviral vectors and compositions for the highly efficient transduction of T cells.
    Type: Application
    Filed: April 13, 2021
    Publication date: September 30, 2021
    Applicant: GenVec, Inc.
    Inventors: Sebastien M. Maloveste, Damodar Ettyreddy, Douglas E. Brough
  • Publication number: 20210269827
    Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 2, 2021
    Applicant: GenVec, Inc.
    Inventors: Lisa Wei, Douglas E. Brough, C. Richter King
  • Patent number: 11034975
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexone protein, and/or fiber protein.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 15, 2021
    Assignee: GenVec, Inc.
    Inventors: Jason G. D. Gall, Duncan McVey, Douglas E. Brough
  • Patent number: 10947560
    Abstract: The invention provides a replication-deficient serotype 28 adenoviral vector characterized by comprising a portion of a serotype 45 adenoviral hexon protein and/or a portion of a serotype 45 fiber protein in place of the endogenous serotype 28 hexon and/or fiber protein.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: March 16, 2021
    Assignee: GenVec, Inc.
    Inventors: Lisa Wei, Douglas E. Brough, C. Richter King
  • Publication number: 20210040502
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Application
    Filed: August 25, 2020
    Publication date: February 11, 2021
    Applicant: GenVec, Inc.
    Inventors: Douglas E. Brough, Jason G.D. Gall, Duncan McVey
  • Patent number: 10792376
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: October 6, 2020
    Assignee: GenVec, Inc.
    Inventors: Duncan McVey, Douglas E. Brough, Jason G. D. Gall
  • Patent number: 10787682
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: September 29, 2020
    Assignee: GenVec, Inc.
    Inventors: Douglas E. Brough, Jason G. D. Gall, Duncan McVey
  • Patent number: 10780153
    Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: September 22, 2020
    Assignee: GenVec, Inc.
    Inventors: Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder
  • Patent number: 10640776
    Abstract: The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: May 5, 2020
    Assignee: GenVec, Inc.
    Inventors: Jason G. D. Gall, Douglas E. Brough, C. Richter King
  • Publication number: 20190316152
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Application
    Filed: February 22, 2019
    Publication date: October 17, 2019
    Applicant: GenVec, Inc.
    Inventors: Jason G.D. Gall, Duncan McVey, Douglas E. Brough
  • Publication number: 20190269794
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Application
    Filed: March 13, 2019
    Publication date: September 5, 2019
    Applicant: GenVec, Inc.
    Inventors: Duncan McVey, Douglas E. Brough, Jason G.D. Gall
  • Publication number: 20190247483
    Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Applicant: GenVec, Inc.
    Inventors: Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder
  • Publication number: 20190233845
    Abstract: The invention provides adenoviral vectors and compositions for the highly efficient transduction of T cells.
    Type: Application
    Filed: September 29, 2017
    Publication date: August 1, 2019
    Applicant: GenVec, Inc.
    Inventors: Sebastien M. Maloveste, Damodar Ettyreddy, Douglas E. Brough
  • Patent number: 10314901
    Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: June 11, 2019
    Assignee: GenVec, Inc.
    Inventors: Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder
  • Patent number: 10272162
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: April 30, 2019
    Assignee: GenVec, Inc.
    Inventors: Duncan McVey, Douglas E. Brough, Jason G. D. Gall
  • Patent number: 10260074
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: April 16, 2019
    Assignee: GenVec, Inc.
    Inventors: Jason G. D. Gall, Duncan McVey, Douglas E. Brough
  • Publication number: 20190100561
    Abstract: Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided.
    Type: Application
    Filed: October 10, 2018
    Publication date: April 4, 2019
    Applicant: GenVec, Inc.
    Inventors: Lisa Wei, Douglas E. Brough, Christopher Lazarski